cover story
few years witnessed a remarkable
growth in the vaccine market due to
the avian influenza, and infections
like SARS.
One of the remarkable features
of this market is the unique
partnerships even between
competitors. In one example,
GSK and Biological E in 2013
formed a 50/50 joint venture
(JV) for the early stage research
and development of a six-in-one
combination paediatric vaccine to
help protect children in India. If
12
BioVoiceNews | September 2017
approved, the vaccine, which would
combine GSK’s injectable polio
vaccine (IPV) and Biological E’s
pentavalent vaccine for diphtheria,
tetanus, whooping cough (whole
cell pertussis), hepatitis B, and
Haemophilus influenzae type b,
could be the first of its kind.
Key challenges for the vaccine
market
Among the host of challenges, most
important ones are long timelines,
delays, several agencies being